Loading, Please Wait...
CORAL GABLES, Fla., March 18, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today reported financial results for the fourth quarter and year-ended December 31, 2018 and provided a corporate update.
“2018 was a transformational year for Catalyst with the approval of Firdapse® (amifampridine phosphate) tablets, the first and only evidence-based, FDA approved treatment for patients with Lambert-Eaton myasthenic syndrome or LEMS. With this approval, all adult LEMS patients will now have affordable access to Firdapse,” said Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst Pharmaceuticals. “We are pleased with the robust momentum that we have seen since the launch of Firdapse, including patient enrollment forms, the breadth of prescribers, and positive reimbursement trends. In 2019, we will remain laser-focused on the commercial launch of Firdapse, as well as on our efforts in the clinic to evaluate Firdapse as a potential therapy to treat other rare neuromuscular diseases.”
2018 and Recent Highlights
Fourth Quarter and Full-Year 2018 Financial Results
For the year ended December 31, 2018, Catalyst reported a GAAP net loss of $34,003,514, or $0.33 per basic and diluted share, compared to a GAAP net loss of $18,412,377, or $0.21 per basic and diluted share, for the 2017 fiscal year. For 2018, non-GAAP1 net loss was the same as GAAP net loss, as there were no non-GAAP1 adjustments. Excluding non-cash loss of $186,904 attributable to the change in fair value of liability-classified warrants, non-GAAP1 net loss was $18,225,473, or $0.21 per basic and diluted share, for the year ended December 31, 2017.
For the quarter ended December 31, 2018, Catalyst reported a GAAP net loss of $14,499,609, or $0.14 per basic and diluted share, compared to a GAAP net loss of $5,387,698, or $0.06 per basic and diluted share, for the 2017 fiscal year. For the fourth quarter of 2018 and 2017, non-GAAP1 net loss was the same as GAAP net loss as there were no non-GAAP1 adjustments.
Research and development expenses for the year ended December 31, 2018 were $19,919,204, compared to $11,375,237 for the 2017 fiscal year. For the fourth quarter of 2018, research and development expenses were $8,416,969, compared to $3,404,634 for the fourth quarter of 2017. The increase in research and development for 2018 when compared to 2017 is primarily due to increases in consulting expenses as Catalyst prepared to submit its NDA for Firdapse during the first quarter of 2018, milestone expenses relating to the acceptance and approval of Catalyst’s NDA submission, expenses from Catalyst’s medical affairs program, and compensation and related personnel costs as Catalyst expanded its headcount to support its currently ongoing trials and programs. Catalyst expects that costs related to research and development activities will continue to be substantial in 2019 as Catalyst works towards completing trials evaluating Firdapse for the treatment of CMS, MuSK-MG and SMA Type 3, continues its Expanded Access Program for Firdapse, and begins development of a sustained release formulation for Firdapse.
General and administrative expenses for the year ended December 31, 2018 totaled $15,875,961, compared to $7,304,399 in the 2017 fiscal year. For the fourth quarter of 2018, general and administrative expenses totaled $6,926,298, compared to $2,107,152 in the same period in 2017. Pre-commercialization costs of $6,897,483 and $809,584, respectively, were included in general and administrative expense in 2018 and 2017. The increase when compared to 2017 is primarily due to increases in pre-commercialization expenses, and headcount and corporate expenses as Catalyst built up its infrastructure and commercial programs in preparation for the launch of Firdapse in the first quarter 2019. Catalyst expects that going forward general and administrative expenses, excluding commercialization expenses, will be reported as selling expenses and will continue to increase in 2019 as Catalyst continues to expand its operations to support the launch of Firdapse.
During the fourth quarter and year 2018, Catalyst had revenues of $500,000 from its collaboration with Endo for generic Sabril that began during December 2018. Catalyst had no revenues for the fourth quarter or year 2017.
At December 31, 2018, Catalyst had cash and investments of $58.5 million and no debt. Based on its current financial position and its forecasts of available cash, Catalyst believes that it has sufficient funds to support its operations for at least the next 12 months.
More detailed financial information and analysis can be found in Catalyst's Annual Report on Form 10-K for the fiscal year ended December 31, 2018, which was filed with the Securities and Exchange Commission earlier today.
Catalyst management will host an investment-community conference call and webcast at 8:30 a.m. ET, tomorrow, Tuesday, March 19, 2019, to discuss the financial results and provide a corporate update. Investors who wish to participate in the conference call may do so by dialing (877) 407-8912 for domestic and Canadian callers or (201) 689-8059 for international callers. Those interested in listening to the conference call live via the internet may do so by visiting the Investor’s page of the Company's website at www.catalystpharma.com and clicking on the webcast link on the Investor’s home page. A webcast replay will be available on the Catalyst website for 30 days following the call by visiting the Investor’s page of the Company's website at www.catalystpharma.com.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis (MuSK-MG) and spinal muscular atrophy (SMA) Type 3. Catalyst's new drug application for Firdapse® (amifampridine) 10 mg tablets for the treatment of adults with LEMS was recently approved by the U.S. Food & Drug Administration ("FDA"), and Firdapse is now commercially available in the United States. Prior to its approval, Firdapse for LEMS had received breakthrough therapy designation and orphan drug designation from the FDA.
Firdapse is currently being evaluated in clinical trials for the treatment of CMS, MuSK-MG and SMA Type 3 and has received Orphan Drug Designation from the FDA for CMS and myasthenia gravis. Firdapse (amifampridine) 10 mg tablets is the first and only approved drug in Europe for the symptomatic treatment in adults with LEMS.
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including (i) whether Catalyst will be successful in commercializing Firdapse, (ii) whether, even if Catalyst is successful in commercializing Firdapse, Catalyst will become profitable, (iii) whether Firdapse will ever be approved for the treatment of CMS, MuSK-MG, SMA Type 3, or any other disease, and (iv) those other factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2018 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
1 Statements made in this press release include a non-GAAP financial measure. Such information is provided as additional information and not as an alternative to Catalyst's financial statements presented in accordance with U.S. generally accepted accounting principles (GAAP). This non-GAAP financial measure is intended to enhance an overall understanding of Catalyst's current financial performance. Catalyst believes that the non-GAAP financial measure presented in this press release provides investors and prospective investors with an alternative method for assessing Catalyst's operating results in a manner that Catalyst believes is focused on the performance of ongoing operations and provides a more consistent basis for comparison between periods. The non-GAAP financial measure in this press release excludes from the calculation of net loss the expense (or the income) associated with the change in fair value of the liability-classified warrants. Non-GAAP net loss per share is calculated by dividing non-GAAP net loss by the weighted average common shares outstanding.
CATALYST PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
For the Three Months
Ended December 31,
For the Year
Ended December 31,
|Revenues from collaborative arrangement||$||500,000||$||-||$||500,000||$||-|
|Operating costs and expenses:|
|Research and development||$||8,416,969||$||3,404,634||$||19,919,204||$||11,375,237|
|General and administrative||6,926,298||2,107,152||15,875,961||7,304,399|
|Total operating costs and expenses||15,343,267||5,511,786||35,795,165||18,679,636|
|Loss from operations||(14,843,267||)||(5,511,786||)||(35,295,165||)||(18,679,636||)|
|Other income, net||343,658||124,088||1,291,651||454,163|
|Change in fair value of warrants liability||-||-||-||(186,904||)|
|Loss before income taxes||(14,499 609||)||(5,387,698||)||(34,003,514||)||(18,412,377||)|
|Provision for income taxes||-||-||-||-|
|Net loss||$||(14,499 609||)||$||(5,387,698||)||$||(34,003,514||)||$||(18,412,377||)|
|Net loss per share – basic and diluted||$||(0.14||)||$||(0.06||)||$||(0.33||)||$||(0.21||)|
|Weighted average shares
outstanding – basic and diluted
CATALYST PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
|Cash and cash equivalents||$||16,559,400||$||57,496,702|
|Prepaid expenses and other current assets||1,649,781||1,173,744|
|Total current assets||55,187,406||85,187,157|
|Property and equipment, net||245,425||191,385|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Accrued expenses and other liabilities||7,173,987||2,320,587|
|Total current liabilities||9,511,354||4,266,162|
|Accrued expenses and other liabilities, non-current||154,799||157,456|
|Total stockholders’ equity||50,783,809||80,963,812|
|Total liabilities and stockholders’ equity||$||60,449,962||$||85,387,430|
Investor Contact Brian Korb The Trout Group LLC (646) 378-2923 firstname.lastname@example.org Company Contact Patrick J. McEnany Catalyst Pharmaceuticals Chief Executive Officer (305) 420-3200 email@example.com Media Contact David Schull Russo Partners (212) 845-4271 firstname.lastname@example.org